Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 1897       

   Table of Contents      
CLINICAL IMAGES
Year : 2015  |  Volume : 141  |  Issue : 2  |  Page : 247-248

Herpes zoster complicating bortezomib therapy


Clinical Hematology, Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India

Date of Web Publication21-Apr-2015

Correspondence Address:
Subhash Chander Varma
Clinical Hematology, Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-5916.155599

Rights and Permissions

How to cite this article:
Sahu KK, Varma SC. Herpes zoster complicating bortezomib therapy. Indian J Med Res 2015;141:247-8

How to cite this URL:
Sahu KK, Varma SC. Herpes zoster complicating bortezomib therapy. Indian J Med Res [serial online] 2015 [cited 2019 Nov 15];141:247-8. Available from: http://www.ijmr.org.in/text.asp?2015/141/2/247/155599

A 62 year old female patient with multiple myeloma was on follow up in the Haematology clinic, department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, and was receiving bortezomib based chemotherapy given on days 1, 4, 8, and 11 of 35-day cycle. After two such cycles in June 2013, she started developing painful skin lesions on right D9-10 dermatome. On examination erythematous, crusted superficial erosions with a few vesicular lesions were present ([Figure 1] A, B). Tzanck smear showed multinucleated giant cells confirming the diagnosis of herpes zoster ([Figure 1] C, D). It was found that despite advice she did not take acyclovir prophylaxis during chemotherapy which led to this complication. She was given oral valganciclovir 1 g thrice a day for 10 days. Unfortunately, she was lost to follow up. There are theories which explain increased susceptibility of patients on bortezomib to herpes infection [1],[2] . Considering two earlier studies [3],[4] and our case, it is emphasised that acyclovir prophylaxis should be used during bortezomib treatment.
Figure 1 A, B. Well defined erythematous, crusted erosions with a few vesicular lesions (indicated by black arrows in (B) in a linear pattern over the right D 9-10 dermatome. Figure 1 C, D. Light microscopy using tzanck smear and stained with Wright-Giemsa stain showing giant cells.

Click here to view


 
   References Top

1.
Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, et al. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol 2012; 10 : 155-9.   Back to cited text no. 1
    
2.
Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112 : 1593-9.  Back to cited text no. 2
    
3.
Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009; 115 : 229-32.  Back to cited text no. 3
    
4.
Aoki T, Nishiyama T, Imahashi N, Kitamura K. Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study. Jpn J Clin Oncol 2011; 41 : 876-81.  Back to cited text no. 4
    


    Figures

  [Figure 1]


This article has been cited by
1 Necrotizing fasciitis: challenges in diagnosis and management
K K Sahu,A K Mishra,C A Lopez
QJM: An International Journal of Medicine. 2019;
[Pubmed] | [DOI]
2 Erythema ab igne as a complication of cannabinoid hyperemesis syndrome
Kamal Kant Sahu,Ajay Mishra,Leily Naraghi
BMJ Case Reports. 2019; 12(1): e227836
[Pubmed] | [DOI]
3 Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations
Corrado Girmenia,Michele Cavo,Massimo Offidani,Francesco Scaglione,Alessandro Corso,Francesco Di Raimondo,Pellegrino Musto,Maria Teresa Petrucci,Giovanni Barosi
Blood Reviews. 2019;
[Pubmed] | [DOI]
4 ARA-C RELATED RED EAR SYNDROME
Kamal Kant Sahu,Uday Yanamandra,Pankaj Malhotra
Ear, Nose & Throat Journal. 2019; 98(3): 169
[Pubmed] | [DOI]
5 Acute generalised skin rash secondary to the Nystatin Oral Suspension
Kamal Kant Sahu,Ajay Kumar Mishra,Amos Lal,Rahul Gandhi
BMJ Case Reports. 2019; 12(5): e230600
[Pubmed] | [DOI]
6 Disseminated herpes zoster following treatment with benralizumab
Ajay Kumar Mishra,Kamal Kant Sahu,Atem James
The Clinical Respiratory Journal. 2019; 13(3): 189
[Pubmed] | [DOI]
7 Bortezomib
Reactions Weekly. 2015; 1576(1): 63
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References
    Article Figures

 Article Access Statistics
    Viewed581    
    Printed7    
    Emailed0    
    PDF Downloaded264    
    Comments [Add]    
    Cited by others 7    

Recommend this journal